Novartis Hits Spartalizumab Phase III Setback In Melanoma
IO MAPK Inhibitor Combination Hopes Dashed
Executive Summary
Novartis’s attempts to enter the PD1 market by combining its investigational immunotherapy spartalizumab with its Tafinlar and Mekinist BRAF/MEK combination have come unstuck, leaving Roche to the field.
You may also be interested in...
Novartis CEO: Oncology Treatment Almost Back To Pre-COVID Levels
The Swiss major's oncology business performed well in the third quarter with Kisqali sales catching the eye despite the specific problems that the pandemic has brought for breast cancer patients.
Novartis's Tislelizumab Takes First Step On US Approval Path
Novartis has filed the PD-1 inhibitor tislelizumab, licensed from BeiGene, for second-line esophageal cancer with the FDA, the first submission outside China for the closely-watched therapy.
J.P. Morgan Day 2: Pharma Offers (Some) Views On Drug Pricing Reform
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Novartis explains its PD-1 deal; Biogen partners with Apple; Sanofi and Merck discuss business development priorities; and why AbbVie is confident it can grow without relying on deals.